A 66-year-old patient with depression on escitalopram (Lexapro) wants to switch to venlafaxine (Effexor); what are venlafaxine’s mechanism and side effects, and how should escitalopram be tapered and venlafaxine started?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Lexapro to Effexor in a 66-Year-Old Patient

Yes, you can switch from escitalopram (Lexapro) to venlafaxine (Effexor) in this 66-year-old patient with depression, and the evidence supports no significant efficacy difference between these agents, though venlafaxine has a higher side effect burden. 1

Mechanism of Action

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks reuptake of both serotonin and norepinephrine, with somewhat greater potency for serotonin at lower doses 2. At doses below 150 mg/day, it acts primarily as a selective serotonin reuptake inhibitor; norepinephrine reuptake inhibition becomes clinically significant at higher doses (≥150 mg/day). This is distinct from escitalopram, which is the most selective serotonin reuptake inhibitor available and acts only on serotonin 3.

Side Effects of Venlafaxine

The most common side effects are nausea (most frequent reason for discontinuation), vomiting, sweating, dizziness, dry mouth, and sexual dysfunction 4. In the 66-year-old age group specifically:

  • Nausea and vomiting: Higher incidence than with SSRIs like escitalopram 4
  • Cardiovascular effects: Dose-dependent increases in blood pressure and heart rate; monitor blood pressure regularly 4, 2
  • Sexual dysfunction: Comparable to SSRIs 4
  • Discontinuation symptoms: More severe than escitalopram if stopped abruptly 5
  • Sweating, reduced salivation, orthostatic dizziness: Common, especially during initial weeks 6

Important for this 66-year-old patient: Venlafaxine requires dose adjustment in renal impairment, and therapeutic drug monitoring is recommended in elderly patients with declining kidney function 7. The half-life of escitalopram increases by 50% in patients ≥65 years 8.

How to Switch: Direct Cross-Taper Method

For switching from escitalopram to venlafaxine, use a direct cross-taper over 1-2 weeks 6, 9:

Week 1:

  • Reduce escitalopram from current dose to 50% (e.g., if on 10 mg, reduce to 5 mg)
  • Start venlafaxine XR at 37.5 mg daily in the morning

Week 2:

  • Stop escitalopram completely
  • Increase venlafaxine XR to 75 mg daily

Weeks 3-4:

  • Titrate venlafaxine XR to target dose of 150 mg/day (can go up to 225 mg/day if needed for response)
  • Monitor weekly for side effects and symptom improvement 6

Critical safety note: There is NO required washout period between escitalopram and venlafaxine, as neither is an MAOI 10. A 14-day washout is only required when switching to/from MAOIs 10.

Monitoring During the Switch

Monitor within 1-2 weeks of starting the switch 4:

  • Blood pressure (weekly for first month due to venlafaxine's hypertensive effects)
  • Emergence of nausea, sweating, dizziness (most common in weeks 1-3, typically improve with continued treatment 6)
  • Worsening depression, suicidal thoughts, agitation, or unusual behavioral changes 10
  • Discontinuation symptoms from escitalopram (anxiety, irritability, dizziness, sensory disturbances)

Expected Efficacy

The evidence shows no clinically significant difference in efficacy between escitalopram and venlafaxine 1, 5, 3. In head-to-head trials, both achieved similar remission rates (41% for escitalopram vs. 37% for venlafaxine) 3. However, escitalopram was significantly better tolerated with lower discontinuation rates due to adverse events (4.1% vs. 16%) 3.

Common Pitfalls to Avoid

  • Do not stop escitalopram abruptly: Gradual taper reduces withdrawal symptoms 8, 9
  • Do not start venlafaxine at high doses: Rapid titration to 225 mg increases side effects without improving efficacy 3
  • Do not ignore blood pressure: Venlafaxine causes dose-dependent hypertension 4, 2
  • Do not assume lack of response means inadequate dose: Assess response at 6-8 weeks before increasing dose 4

Reassessment Timeline

If no adequate response after 6-8 weeks on venlafaxine 150 mg/day, consider dose increase to 225 mg/day or alternative strategies 4. The evidence shows that switching between second-generation antidepressants (like this switch) yields similar outcomes to other second-step strategies 1.

Related Questions

What is the recommended protocol for switching an adult patient from atomoxetine (Strattera) to venlafaxine (Effexor)?
What is the appropriate cross‑taper schedule to switch a patient from venlafaxine (Effexor XL) 300 mg to sertraline (Zoloft)?
What is the recommended approach for switching a patient from citalopram (Celexa) 10mg to Lexapro (escitalopram)?
Can a patient switch from Celexa (citalopram) to Pristiq (desvenlafaxine) after a 4‑day washout period?
What is the recommended dosing schedule for venlafaxine extended‑release (ER) in adults, including adjustments for elderly patients, hepatic impairment, and renal impairment?
For a male patient taking donepezil (Aricept) and quetiapine (Seroquel), which ECG parameters should be monitored?
Can you provide a medical abstract citation supporting that, based on the Bradford Hill criteria, the veteran’s biopsy‑confirmed discoid lupus erythematosus (negative antinuclear antibody) is at least as likely as not (probability ≥ 50 %) caused by the toxic exposures—including intense ultraviolet radiation, inorganic dust, burn‑pit emissions, contaminated soil, and heat‑related skin barrier disruption—experienced during a 90‑day Kuwait deployment?
Can a patient with allergies to penicillin, sulfonamides, and cephalosporins receive Zosyn (piperacillin/tazobactam)?
Does metformin pose a risk of urinary obstruction or urinary retention?
Can I give ertapenem to this patient?
Is this lesion a bug bite or an infected hair follicle (folliculitis) given the presence of a black head on a cystic area with redness and warmth?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.